A study to investigate Safety, Tolerability, and Pharmacokinetics of AZD7503 in participants with suspected NASH.

Exclusion Criteria

• 1. Evidence of any clinical important condition which in the investigator opinion makes it undesirable for the participant to participate in the study
• 2. Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of study intervention
• 3. History of liver transplant or presence or history of hepatic disease other than NASH or histological or imaging evidence of cirrhosis.
• 4. Human immunodeficiency virus (HIV) infection, seropositive for Hepatitis B (HBV)virus, seropositive for Hepatitis C virus (HCV)
• 5. History of excessive alcohol consumption
• 6. Uncontrolled high blood pressure
• 7. Any clinically important abnormalities in ECG
• 8. Suspected history of illicit drug abuse
• 9. Clinically important abnormalities in urine and blood laboratory results
• 10. Changes in concomitant medication within 1 month of screening
• 11. Received another investigational drug within 90 days of administration of study intervention in this study
• 12. Has received any chemical entity or investigational drug targeting HSD17B13 (eg, ARO-HSD or ALN-HSD).